• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

major depressive disorder

Cartoon of businessmen standing around a broken target
Biotech

J&J ends phase 3 depression program over 'insufficient efficacy'

J&J has stopped development of aticaprant as an adjunctive treatment for major depressive disorder but will explore other development opportunities.
Nick Paul Taylor Mar 7, 2025 4:55am
A puzzle of the brain with one missing piece

Takeda regains home rights to depression drug from Neurocrine

Jan 28, 2025 4:16am
Baseball sitting in a glove against a dark background

After 3rd phase 3 strike, Relmada's depression drug is out

Dec 9, 2024 2:30pm
Close up of hallucinogenic mushrooms

Cybin psychedelic reduces depression severity after 12 months

Nov 18, 2024 12:57pm
failure crash no fail rocket cancelled end

Alto's midphase depression trial falls flat

Oct 23, 2024 4:47am
Man on chair with head in hand

Supernus links depression drug to fast responses in ph. 2 trial

Oct 18, 2024 9:17am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings